Molecular Partners AG

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

European biotechs increasingly look to go public on the US NASDAQ rather than list on their local markets but they should not forget the benefits of running their operations closer to home. That's the

“Switzerland has four main sources of new biotech activity,” Swiss Biotech Association CEO Michael Altorfer told Scrip . “The first source is spin-offs from academic centres in the country, the secon

While Novartis AG and Roche Holding AG are the names that spring to mind when thinking of Switzerland, Swiss Biotech Association CEO Michael Altorfer argues that big pharma is just the tip of the